NCT00083551: UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after...
Dec 10, 2004
272
NCT00081939: UARK 2003-33, Total Therapy III
UARK 2003-33, Total Therapy III Total Therapy 3 The UARK 2003-33, Total Therapy III - There have been two previous Total Therapy studies...
Dec 9, 2004
257
NCT00098475: Phase 3: Lenalidomide and Dexamethasone With or Without Thalidomide in Multiple Myeloma
ECOG-ACRIN Cancer Research Group ECOG E4A03 NCT00098475: Phase 3: Lenalidomide and Dexamethasone With or Without Thalidomide in Treating...
Dec 9, 2004
288
PMID 6546971: Effective treatment of advanced multiple myeloma refractory to alkylating agents
N Engl J Med May 24, 1984 Effective treatment of advanced multiple myeloma refractory to alkylating agents. Barlogie B, Smith L,...
Dec 4, 2004
263
NCT00028886: Phase 3 - Combination Chemotherapy With or Without Thalidomide in Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may...
Dec 3, 2004
323